MLAB

$125.48+2.88%visit website

MESA LABORATORIES INC /CO/

Market Cap

$702M

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Life Sciences Tools & Services

Beta (raw)

1.06

60mo monthly vs SPY

P/E (TTM)

147.6

TTM to Jun 2026 · diluted EPS

P/S (TTM)

2.8

TTM to Jun 2026 · revenue

P/B

3.7

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

26.7

TTM to Jun 2026 · EV incl. net debt

Flagged input, hover for details

Loading…

Financial Statements

USD thousands	Q2 FY2025 Sep 30, 2025	Q3 FY2025 Dec 31, 2025	Q4 FY2026 Mar 31, 2026	Q1 FY2027 Jun 30, 2026	TTM Jun 30, 2026
Revenue	60,737	65,126	63,724	60,138	249,725
Cost of revenue	23,406	23,331	21,519	21,126	89,382
Gross profit	37,331	41,795	42,205	39,012	160,343
Research & development	5,048	5,029	5,247	4,725	20,049
Total operating expenses	32,607	33,820	39,457	31,981	137,865
Operating income	4,724	7,975	2,748	7,031	22,478
Interest expense	2,862	3,036	2,596	2,363	10,857
Pretax income	1,999	4,596	(1,593)	4,353	9,355
Income tax	(477)	966	2,543	1,523	4,555
Net income	2,476	3,630	(4,136)	2,830	4,800
EPS (basic) ($)	0.45	0.66		0.50	0.85
EPS (diluted) ($)	0.45	0.65		0.49	0.85
Weighted avg. shares (basic)	5,512	5,532		5,657
Weighted avg. shares (diluted)	5,535	5,565		5,757

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 10, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 13, 2026 accepted 8:00 AM ET	2.05Restructuring costs7.01Reg FD disclosure	Document SEC ↗
Sep 8, 2026 accepted 3:26 PM ET	5.07Shareholder vote	Document SEC ↗
Aug 10, 2026 accepted 4:03 PM ET	2.02Earnings release	Document SEC ↗
Jul 30, 2026 accepted 5:18 PM ET	5.05Code of ethics	Document SEC ↗
Jun 15, 2026 accepted 5:29 PM ET	5.02Officer / director change	Document SEC ↗
May 27, 2026 accepted 8:00 AM ET	2.02Earnings release	Document SEC ↗
Mar 23, 2026 accepted 4:25 PM ET	5.02Officer / director change	Document SEC ↗
Mar 9, 2026 accepted 5:02 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Feb 3, 2026 accepted 8:00 AM ET	2.02Earnings release	Document SEC ↗
Nov 6, 2025 accepted 4:22 PM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

76%

W/W +16.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Buy Activity

Buy Velocity Score

8.84x

Avg Daily Buying (90d)

88.8 sh/day

Baseline Daily Buying

25.0 sh/day

Unique Buyers (90d)

Sell Activity

Sell Velocity Score

5.59x

Avg Daily Selling (90d)

78.8 sh/day

Baseline Daily Selling

33.8 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-13	2026-08-17	Kadia Siddhartha	President and CEO	Purchase	7,093	$112.80	$800K	7,093	View
2026-08-13	2026-08-17	Tripeny R Tony	Director	Purchase	900	$113.69	$102K	6,298	View
2026-08-13	2026-08-17	Sullivan John James	Director	Sale	7,093	$112.80	$800K	17.8K	View
2026-06-22	2026-06-23	Sakys John	CFO	Sale	2,827	$89.50	$253K	19.8K	View
2026-06-22	2026-06-23	Archbold Brian David	SVP Operations	Sale	2,516	$89.50	$225K	6,377	View